Novartis AG ADR
NYSE: NVS
$104.41
+$0.56 (+0.5%)
Real Time Data Delayed 15 Min.
NVS Articles
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Published:
Last Updated:
ThinkstockNovartis AG (NYSE: NVS) is one of the few companies with good news on a major market sell-off. Unfortunately, it is not big enough news to be moving the shares. The Swiss drug giant...
Published:
Aveo Pharmaceuticals made waves in early trading indications Monday on news of a licensing agreement with Novartis.
Published:
ThinkstockThere are times when a negative piece of news in the BioPharma sector can actually help rival companies. Biogen Inc. (NASDAQ: BIIB) is a stock that has been battered of late, and it is a...
Published:
Novartis is getting ready to steal a lot of hearts with its newest drug. The FDA has approved Entresto tablets for the treatment of heart failure.
Published:
Last Updated:
Owning a few top European stocks in a well-balanced portfolio makes good sense at this juncture, especially with the U.S. markets hovering near all-time highs.
Published:
A new research report from the analysts at Cowen highlights the firm's top health care picks, many of which have some huge upside potential to the posted price targets.
Published:
What are investors, and patients, supposed to think when is launching a generic version of Diovan?
Published:
Last Updated:
Array BioPharma has announced that it had reached a definitive agreement with Novartis to regain full worldwide rights to cancer drug binimetinib.
Published:
Wednesday's top analyst upgrades, downgrades and initiations include American Electric Power, BP, Halliburton, Cypress Semiconductor, J.C. Penney, Schlumberger and SanDisk.
Published:
A new research report from J.P. Morgan, makes the case that the time to buy some of the top stocks in Europe is right now.
Published:
For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.
Published:
Last Updated:
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
Published:
ThinkstockBinary events are often the key element in moving a biotech or health care stock higher. Negative binary results or actions often can move shares drastically lower. We scan our 24/7 Wall...
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations see on Monday, June 9, 2014. They include BioMarin, Family Dollar, Lululemon and SunTrust.
Published: